Knee Disease Articles & Analysis
8 news found
” REVA’s MOTIV device represents a unique breakthrough technology for the treatment of patients suffering from below-the-knee peripheral vascular disease. MOTIV is a drug-eluting bioresorbable peripheral vascular scaffold made from REVA’s proprietary Tyrocore polymer that is designed to dissolve over time, leaving the artery free of a permanent ...
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. ...
After suffering from excruciating knee pain, Art had a knee replacement with the TSolution One Total Knee Application. ...
With the installation of three KneeKG Systems, the project will demonstrate the functionalities and performance of Emovi’s AI Platform combined with its KneeKG technology to the military health system. “Knee pain affects one person out of five and includes sports injuries and structural diseases such as knee osteoarthritis ...
ByEmovi
KneeKGTM is the first in-clinic device that enables healthcare professionals to accurately, objectively, and in real-time assess a patient’s knee(s) in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the biomechanical and functional deficits linked to pain ...
ByEmovi
The Temporary Spur Stent System is a novel retrievable stent designed to treat long, diffuse and severely calcified infrapopliteal disease. The device consists of a patented retrievable stent system having a series of radially expandable spikes designed to create multiple pathways to allow the increased uptake of antiproliferative drugs (“limus” based) into the vessel ...
Food and Drug Administration (FDA) granted Virtue SEB Breakthrough Designations for the treatment of coronary in-stent restenosis and below-the-knee peripheral artery disease. In September 2019, Orchestra BioMed announced CE mark approval for its Moderato® implantable pulse generator system that delivers BackBeat Cardiac Neuromodulation Therapy™ ...
The oral presentations will feature the Virtue® Sirolimus-Eluting Balloon which has Breakthrough Device Designation from the U.S Food and Drug Administration for the treatment of below-the-knee disease and coronary in-stent restenosis, for which the Company has a global strategic partnership with Terumo Corporation. ...